Skip to main content

Table 2 Correlation between pfdhfr / pfdhps genotypes and treatment outcomes to sulphadoxine-pyrimethamine

From: Two novel mutations of pfdhps K540T and I588F, affecting sulphadoxine-pyrimethamine-resistant response in uncomplicated falciparum malaria at Banjar district, South Kalimantan Province, Indonesia

pfdhfr*/pfdhps** genotypes Prevalence (%) (n = 24) Treatment outcomes
ACPR ETF LPF
ANCN I/SAKAA 1 (4.1) 1   
ANRN I/SGE AA 4 (16.7) 2 1 1
ANRN I/SGE AA(588F) 5 (20.8) 1 2 2
ANRN I/SGTG A 6 (25.0)   2 4
ANRNL/SG KAA 4 (16.7) 2 1 1
ANRNL/SGTG A 4 (16.7)   4  
  1. *pfdhfr genotypes are presented at amino acid positions of 16, 51, 59, 108, and 164.
  2. **pfdhps genotypes are presented at amino acid positions of 436, 437, 540, 581, and 613 (and 588).
  3. The bold type indicates amino acid substitution.
  4. ACPR = adequate clinical parasitological response; LPF = late parasitological failure, ETF = early treatment failure.